NEW YORK, August 11, 2016 /PRNewswire/ --
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
At the close on Wednesday, shares in Lexington, Massachusetts headquartered Agenus Inc. saw a drop of 3.60%, ending the day at $5.89. The stock recorded a trading volume of 1.12 million shares, which are above its three months average volume of 1.02 million shares. The Company's shares have surged 21.69% in the last one month, 78.48% in the previous three months, and 29.74% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 27.67% and 43.40%, respectively. Moreover, shares of Agenus, which focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 67.46.
On July 28th, 2016, Agenus reported a net loss attributable to common stockholders of $28.4 million which includes $7.6 million of non-cash expenses for Q2 2016. This compares to a net loss attributable to common stockholders for Q2 2015 of $40.5 million which included $17.3 million of non-cash expenses. Net loss was $0.33 per share, and $0.53 per share, basic and diluted, for the three months ended June 30, 2016 and 2015, respectively. The company reported revenue of $6.59 million in Q2 2016, higher than revenue of $6.38 million in the year ago period. The free research report on AGEN is available at: http://stock-callers.com/registration/?symbol=AGEN
Shares in Vancouver, Canada headquartered ProNAi Therapeutics Inc. ended the day 1.55% lower at $1.90 and with a total volume of 600,455 shares traded. The stock is trading below its 50-day moving average by 19.29%. Shares of the Company, which develops and commercializes drugs based on its DNA interference technology platform for patients with cancer and hematological malignancies, have an RSI of 44.16. The complimentary report on DNAI can be downloaded at: http://stock-callers.com/registration/?symbol=DNAI
On Wednesday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. finished 1.37% lower at $12.26 with a total volume of 463,520 shares traded. The stock has advanced 6.61% in the last one month, 39.48% over the previous three months, and 31.69% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 8.67% and 29.29%, respectively. Additionally, shares of Vanda Pharmaceuticals, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 61.34.
On August 1st, 2016, Vanda Pharmaceuticals announced that HETLIOZ® (tasimelteon) is available for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in Germany. In July 2015, the European Commission approved HETLIOZ® for the treatment of Non-24 in totally blind adults in all 28 European Union member states as well as European Economic Area members Iceland, Liechtenstein and Norway. Visit us today and download our complete research report on VNDA for free at: http://stock-callers.com/registration/?symbol=VNDA
Cambridge, Massachusetts headquartered Genocea Biosciences Inc.'s shares recorded a trading volume of 192,943 shares at the end of yesterday's session and closed the day at $4.64, plummeting 6.26%. The stock has advanced 3.80% in the last one month and 25.75% in the previous three months. The Company's shares are trading above their 50-day moving average by 8.71%. Additionally, shares of Genocea Biosciences, which discovers and develops novel vaccines and immunotherapies to treat infectious diseases, have an RSI at 59.02.
On August 04th, 2016, Genocea Biosciences reported net loss of $11.0 million for Q2 ended June 30, 2016, compared to a net loss of $10.3 million for the same period in 2015. The company reported that R&D expenses for the quarter ending June 30, 2016 decreased $0.3 million, to $6.7 million, from the same period in 2015. The decrease was driven by the conduct of a smaller Phase 2 trial for GEN-003 in comparative quarterly periods and lower GEN-003 manufacturing costs due to the timing of activities in support of clinical trial supply. Get free access to your technical report on GNCA at: http://stock-callers.com/registration/?symbol=GNCA
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA